Sort   by:  
 Page size 
ProteomicsThe Combination of Remdesivir and Ivermectin Exerts Highly Potent and Synergistic Antiviral Activity Against Murine Coronavirus and SARS-CoV-2 Infections
The COVID-19 pandemic highlighted the urgent need to develop effective and broad-spectrum antiviral therapies against coronaviruses. One strategy to address this concern is combination therapy using repurposed drugs against zoonotic viruses with pandemic potential. We previously demonstrated that th...
ORGANISM(S): Mus musculus (Mouse) Betacoronavirus 
2026-09-07 | PXD073706 | Pride
Remdesivir  ivermectin  combination therapy  repurposed drugs  murine hepatitis virus  proteomics  transcriptomics 
ProteomicsThe potential of remdesivir to affect function, metabolism and proliferation of in vitro heart and kidney models
Here, we performed an in vitro toxicity assessment for remdesivir at clinically relevant concentrations around the cmax of 9 µM using H9c2 rat cardiomyoblasts and neonatal mouse cardiomyocytes (NMCM) as heart models and rat NRK-52E cells and human RPTEC/TERT1 cells as kidney models. Due to the tende...
ORGANISM(S): Homo sapiens (Human) Mus musculus (Mouse) 
2022-05-24 | PXD029311 | Pride
Cardiotoxicity Covid-19 Mitochondrial toxicity Nephrotoxicity Nucleoside analogue Remdesivir 
GenomicsElucidation of remdesivir cytotoxicity pathways through genome-wide CRISPR/Cas9 screening and transcriptomics
Elucidation of remdesivir cytotoxicity pathways through genome-wide CRISPR/Cas9 screening and transcriptomics
PRJNA647903 | ENA
GenomicsRemdesivir-induced emergence of SARS-CoV2 variants in patients with prolonged infection
Remdesivir-induced emergence of SARS-CoV2 variants in patients with prolonged infection
PRJEB50471 | ENA
TranscriptomicsElucidation of remdesivir cytotoxicity pathways through genome-wide CRISPR/Cas9 screening and transcriptomics
The adenosine analogue remdesivir has emerged as a front-line antiviral treatment for SARS-CoV-2, with preliminary evidence that it reduces the duration and severity of illness. As clinical trials are ongoing, the full side effect profile of remdesivir is not yet known. Prior clinical studies have i...
ORGANISM(S): Homo sapiens 
2020-09-08 | GSE154936 | GEO
GenomicsGene expression of SARS-CoV-2-infected Vero E6 cells with remdesivir treatment
Gene expression of SARS-CoV-2-infected Vero E6 cells with remdesivir treatment
PRJNA698644 | ENA
GenomicsDeep sequencing analysis of the mutant spectrum and consensus sequences of SARS-CoV-2 replicating in the absence or presence of remdesivir, ribavirin and remdesivir + ribavirin
Synergism between remdesivir and ribavirin leads to SARS-CoV-2 extinction in cell culture
PRJEB66908 | ENA
TranscriptomicsGene expression of SARS-CoV-2-infected Vero E6 cells with remdesivir treatment
RNA sequencing was performed on control and SARS-CoV-2 infected Vero E6 cells, with or without remdesivir treatment to study the biological changes after SARS-CoV-2 infection and to evaluate the effectiveness of remdesivir on the gene expression level. 500,000 Vero E6 cells were seeded in 6-well pla...
ORGANISM(S): Chlorocebus sabaeus 
2021-02-02 | GSE165955 | GEO
GenomicsRemdesivir has previously unknown anti-viral immunomodulatory properties through the Adenosine A2A Receptor pathway
Remdesivir has previously unknown anti-viral immunomodulatory properties through the Adenosine A2A Receptor pathway
PRJNA991577 | ENA
UnknownRemdesivir: First Approval.
Not available
S-EPMC7459246 | biostudies-literature
Sort   by:  
 Page size